Core Viewpoint - The company reported a mixed performance in 2024, with a notable increase in revenue from its key products despite challenges in overseas business and raw material procurement [2][8]. Financial Performance - The total revenue for 2024 was 770 million yuan, representing a year-on-year growth of 2.88% [8]. - The net profit attributable to shareholders was 177 million yuan, showing a year-on-year increase of 12.21% [8]. - The gross profit margin reached 58.56%, an increase of 0.98 percentage points compared to the previous year [8]. Product Performance - The lens business revenue grew by 8.72% compared to 2023, indicating the effectiveness of the focus on major products [2]. - The PMC Ultra Bright series saw a significant revenue increase of 45.6% year-on-year, with growth trends continuing into Q1 2025 [2][11]. - The "Easy Control" series generated sales of 50.13 million yuan in Q1 2025, reflecting a year-on-year growth of 22.1% [9]. Market Strategy - The company has permanently exited the price war and shifted focus to high-end product development and brand building since 2019 [8]. - The company aims to expand its brand presence internationally, particularly in markets like Japan, Southeast Asia, and parts of Europe [12]. Industry Trends - The market for defocus lenses is experiencing rapid growth, with many companies entering this segment [9]. - Despite price wars initiated by some foreign brands, the negative impact is gradually diminishing [9]. Sales Channels - The sales strategy includes a mix of direct sales and distribution through 66 partners, including medical channels [11]. - The company has only one model experience store to assist clients in improving transaction efficiency rather than competing with them [11].
直击股东大会 | 利润增速高于收入增速 明月镜片：退出低价、主打大单品，下一步做品牌出海